Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs). These innovative, off-the-shelf products are designed to meet pressing needs in vascular reconstruction and chronic disease management, improving patient outcomes and potentially reducing healthcare expenses. Leveraging its advanced technology platform, Humacyte is strategically positioned to drive innovation in transplantation and tissue engineering, thereby cementing its status as a transformative leader within the rapidly evolving landscape of medical therapies.
| Revenue (TTM) | $2.12M |
| Gross Profit (TTM) | $-79.37M |
| EBITDA | $-103.23M |
| Operating Margin | -6649.00% |
| Return on Equity | -548.00% |
| Return on Assets | -49.90% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.11 |
| Price-to-Book | 3.50 |
| Price-to-Sales (TTM) | 51.80 |
| EV/Revenue | 45.15 |
| EV/EBITDA | 4.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 34.90% |
| Shares Outstanding | $277.80M |
| Float | $250.79M |
| % Insiders | 5.67% |
| % Institutions | 26.22% |
Volatility is currently expanding
– Founder & CEO Laura Niklason, M.D., Ph.D., to deliver invited talk on engineering the microenvironment to accelerate vascular regeneration.
DURHAM, N.C, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the three months and nine months ended September 30, 2026, on Tuesday, November 10, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.
- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a meaningful new option.”
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.4, indicating a -6.5% shift from the previous trading day.
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.36, signifying a -7.88% move from its prior day's close.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company's Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HUMA and any ticker you trade — then tracks every position and per-strategy win rate.
